Pharma News – 26 July

Pharma news updates– 26 July 2020

Brinton Pharma has received DCGI’s approval for marketing Faviton in India:

Pharma News – 26 July: Favipiravir was approved by the DCGI[1] in June 2020 under the emergency use authorization. This medication was found to be effective in treating Covid-19 patients. Clinical evidence obtained from various parts of the globe has proved its efficacy in mild to moderate Covid-19 patients.

On 24 July 2020, Brinton Pharmaceuticals announced that their generic version of Favipiravir had received the DCGI’s approval. The company said that the generic version of this drug is called Faviton. They further added that this drug can be administered orally unlike the other intravenous administrations available in the market.

The drug firm said that Faviton will be available as 200 mg tablets and is to be exported globally. This drug will be sold in strips of 10 tablets and boxes of 50 tablets. The shelf life of this product is 90 days. Faviton is currently priced at Rs. 59 per tablet.

Pharma News – 26 July

Around 30,000 Indians have succumbed to the pandemic as of 24 July 2020. The total number of cases rose to approximately 1,269,532. The number of patients recovered on 24 July 2020 was around 28,557 patients. This in turn caused the total number of recovered patients to rise to 803,286. The recovery rate has also increased to a whopping amount of 63.18%. As of 24 July 2020, the total number of active cases stood at around 436,015. This has increased the gap between the number of recovered and active cases.

The central government is also sending teams of experts to the areas that are witnessing a surge in the number of cases. Teleconsultation programs are also being conducted by the All India Institute of Medical Sciences (AIIMS).

Pharma News – 26 July

The fatality rate in India is around 2.41% and this is gradually declining. A made in India non-invasive ventilator called SwasthVayu is also under development. This ventilator is being made by National Aerospace Laboratories (NAL) in collaboration with Manipal Hospitals and CSIR-IGIB[2].

Abbreviation:

  • 1. Drugs Controller General of India
  • Council of Scientific and Industrial Research – Institute of Genomic and Integrative Biology

2.Jenburkt Pharma launches Favivent in the Indian market:

Pharma News – 26 July: Favipiravir is an antiviral drug that was developed in Japan and used for treating influenza. This drug was approved by the DCGI[1] for the treatment of mild to moderate Covid-19 cases in the country.

Favipiravir is sold by Glenmark Pharmaceuticals under the brand name ‘Fabiflu’ and priced at Rs.75 per tablet. Recently, on 24 July 2020, Brinton Pharmaceuticals announced the launch of its generic version of Favipiravir. This is called as Faviton and is sold at Rs.59 per tablet.

Jenburkt Pharmaceuticals have also announced the launch of their version of Favipiravir on 25 July 2020. The drug firm has named this generic version as ‘Favivent’ and it is priced at Rs.39 per tablet. This tablet is marketed as strips of 10 tablets each. The strength of each tablet is 200 mg.

Pharma News – 26 July

The company has claimed that the Favivent will be manufactured in its pharmaceutical plant in Telangana.

Abbreviation: 1. Drugs Controller General of India

3.Cipla receives DCGI’s approval for marketing ciplenza in India:

Cipla Limited has announced the launch of ‘Ciplenza’ post-approval from the DCGI[1]. The company has claimed that Ciplenza is the brand name of its generic version of Favipiravir. It is approved for treating Covid-19 patients.

Pharma News – 26 July

The drug firm has announced that Ciplenza will be launched in the market from the first week of August 2020. Each tablet is to be priced at Rs.68.

Pharma News – 26 July

The company plans to ensure continuous supply through hospitals and open channels especially in regions with high caseloads.

Ciplenza was developed by Cipla in collaboration with CSIR-IICT[2]. CSIR-IICT designed a cost-effective plan for synthesizing Favipiravir. This technology was handed over to Cipla to ensure that the manufacturing and marketing of this drug can be done on a commercial scale.

Pharma News – 26 July

Favipiravir is an oral antiviral drug that was developed by Fuji Pharma in Japan. It has shown promising results in the clinical trials conducted on mild to moderate Covid-19 patients.

In June 2020, the DCGI had approved the manufacture and sale of Favipiravir by Glenmark Pharmaceuticals. Other drug firms such as Dr.Reddy’s Laboratories have also signed a tripartite agreement with two international firms in Japan and UAE[3]. This agreement was signed for the development, manufacture and sale of Avigan.

Abbreviation:

  • 1. Drugs Controller General of India
  • 2. Council of Scientific and Industrial Research – Indian Institute of Chemical Technology
  • 3. the United Arab Emirates

Read more

References:

Leave a Comment

Your email address will not be published. Required fields are marked *